Show Summary Details
Page of

Anti-arrhythmics in critical illness 

Anti-arrhythmics in critical illness
Chapter:
Anti-arrhythmics in critical illness
Author(s):

John LeMaitre

and Jan Kornder

DOI:
10.1093/med/9780199600830.003.0038
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 29 November 2020

Anti-arrhythmic drugs (AADs) are an important component of the pharmacological arsenal used in the management of the critically-ill patient. The benefits of AADs, as well as their potential disadvantageous side effects, largely depend on their effects upon the cardiac action potential. AADs can be broadly grouped according to their cellular actions, upon which their clinical effects depend. However, there is substantial cross-over amongst the groups in terms of these actions and efficacy for particular arrhythmias, and also for side effects. Amiodarone exhibits a broad spectrum of antiarrhythmic activity and is often the most useful AAD for the critically-ill patient where short-term use reduces concerns relating to toxic side effects associated with chronic administration. However, each of the other available AADs have their uses for particular scenarios in the critically-ill patient, although attention needs to be paid to comorbidities to attenuate the risk of adverse response. AADs are pro-arryhthmic in 5-10% of patients with potential lethal consequences, and the use of AADs in the critically-ill patient should be considered very carefully as correction of the underlying substrate may be sufficient in some circumstances to resolve the index arryhthmia.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.